Dear Research Community,

Below are COVID-19 funding opportunities recently released from the NIH and the funding opportunity database SPIN. The first table of InfoEd funding opps is a summary followed by a second with more detailed information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserve are posted on GCO's Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

From: Table of Contents for the NIH Guide for Grants & Contracts On Behalf Of Guide TOC
Sent: Friday, August 7, 2020 3:00 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Funding Opportunities and Notices for 08-07-2020 (The NIH Guide TOC)

USE CAUTION: External Message.
NIH Guide for Grants and Contracts (Web Version)

Weekly NIH Funding Opportunities and Notices for August 7, 2020

General Notices

- Request for Information (RFI): Fostering Innovative Research to Improve Mental Health Outcomes Among Minority and Health Disparities Populations
  (NOT-MH-20-073) National Institute of Mental Health

Notice of Changes to Funding Opportunities

- Notice of Correction to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" for Award Information about Clinical Trials
  (NOT-OD-20-149) National Institutes of Health

- Notice of Change to Funding Announcement (NOT-OD-20-048) by the Office of Research on Women's Health (ORWH), "Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)"
  (NOT-OD-20-156) Office of Research on Women's Health

- Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program
  (NOT-OD-20-157) National Institutes of Health I Office of Research on Women's Health

Notices of Special Interest

  (NOT-OD-20-159) National Institutes of Health I National Library of Medicine

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

Additional NIH Notices of Special Interest and Funding Opportunities that were released in this week's NIH Guide for Grants and Contracts are included in the InfoEd tables below.
## SPIN Table 1 - Summary

*Links below connect to more detailed information in Table 2.*

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>043741</td>
<td><strong>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme</strong></td>
<td>International AIDS Society</td>
<td></td>
<td>01-Oct-2020</td>
<td>300,000 USD</td>
</tr>
<tr>
<td>097151</td>
<td>RFA-OD-20-014 -- Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>RFA-OD-20-014</td>
<td>21-Aug-2020</td>
<td>600,000 USD</td>
</tr>
<tr>
<td>097596</td>
<td>Understanding the Factors that Affect the Detection and Variability of SARS-CoV-2 in Wastewater</td>
<td>Water Research Foundation</td>
<td></td>
<td>10-Aug-2020</td>
<td>300,000 USD</td>
</tr>
<tr>
<td>097610</td>
<td>J-PAL Africa’s Digital Identification and Finance Initiative (DigiFI Africa)</td>
<td>Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>250,000 USD</td>
</tr>
<tr>
<td>097626</td>
<td>J-PAL North America Short Term Research Management Program (STReaM)</td>
<td>Poverty Action Lab (J-PAL Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097627</td>
<td>J-PAL North America US Health Care Delivery Initiative (HCDI)</td>
<td>Poverty Action Lab (J-PAL Jameel (Abdul Latif)</td>
<td></td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097665</td>
<td>Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)</td>
<td>National Science Foundation</td>
<td>NSF 20-105</td>
<td>Continuous</td>
<td>Not Specified</td>
</tr>
<tr>
<td>097716</td>
<td>COVID-19 Private Sector Engagement &amp; Partnership Fund RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to</td>
<td>Department of State</td>
<td>SFOP0007088</td>
<td>28-May-2021</td>
<td>1,000,000 USD</td>
</tr>
<tr>
<td>097717</td>
<td>National Institutes of Health RFA-TR-20-003</td>
<td>Continuous</td>
<td>RFA-TR-20-003</td>
<td>9,000,000 USD</td>
<td>Specified</td>
</tr>
<tr>
<td>RFA-OD-20-015</td>
<td>Treat COVID-19 Sequelae (U01 Clinical Trial Required)</td>
<td>Health/DHHS</td>
<td>15-Aug-2020</td>
<td>4,000,000 USD</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------------------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>RFA-OD-20-019</td>
<td>RFA-OD-20-019 -- Emergency Awards: RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>31-Aug-2020</td>
<td>16,000,000 USD</td>
<td></td>
</tr>
<tr>
<td>RFA-OD-20-020</td>
<td>RFA-OD-20-021 -- Emergency Awards: RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>18-Aug-2020</td>
<td>1,710,531 USD</td>
<td></td>
</tr>
<tr>
<td>RFA-OD-20-022</td>
<td>RFA-OD-20-022 -- Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)</td>
<td>National Institutes of Health/DHHS</td>
<td>15-Sep-2020</td>
<td>750,000 USD</td>
<td></td>
</tr>
<tr>
<td>RFA-OD-20-023</td>
<td>RFA-OD-20-023 -- Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory</td>
<td>National Institutes of Health/DHHS</td>
<td>31-Aug-2020</td>
<td>Not Specified</td>
<td></td>
</tr>
</tbody>
</table>
### Table 2

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>043741</td>
<td>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme</td>
<td>International AIDS Society</td>
<td>01-Oct-2020</td>
<td>300,000 USD</td>
<td></td>
</tr>
</tbody>
</table>

**Contact Name:** cipher@iasociety.org  
**Contact Telephone:** +41-(0)22-7 100 800  
**Contact Email:** cipher@iasociety.org  
**Sponsor Website:** Link to sponsor website  
**Program URL:** Link to program URL  
**Deadline Dates (ALL)**: 01-Oct-2020

**Synopsis:**

The CIPHER Grant Programme directly supports the development of early-stage investigators, awarding up to US$150,000 for up to two years to address research gaps in paediatric and adolescent HIV in resource-limited settings. The purpose of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme is to fund research projects with the potential to address critical research questions that remain unanswered in the global response in order to inform policy change and ensure better outcomes in infants, children and adolescents living with and affected by HIV in resource-limited settings. Designed for early-stage investigators, a key aim of the programme is to build research capacity within resource-limited settings by fostering the next generation of investigators in paediatric and adolescent HIV. It is intended to attract young investigators from inside and outside the field of HIV. This will help encourage innovative ideas and lead to the design of evidence-based approaches and interventions to overcome major obstacles in the field.
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**Understanding the Factors that Affect the Detection and Variability of SARS-CoV-2 in Wastewater**

- **Contact Name:** Ashwin Dhanasekar
- **Contact Telephone:** 303-734-3423
- **Contact Email:** RFQ5093@waterrf.org
- **Sponsor Website:** Link to sponsor website
- **Program URL:** Link to program URL
- **Deadline Dates (ALL):** 10-Aug-2020
- **Synopsis:**

  The purpose of this RFQ is to identify a Research Team to assist The Water Research Foundation (WRF) in understanding how to optimize sample design for the quantification of SARS-CoV-2 genes in sewage and wastewater.

**J-PAL North America Short Term Research Management Program (STReaM)**

- **Contact Name:** Jameel (Abdul Latif)
- **Contact Telephone:** Continuous
- **Contact Email:** Not Specified
- **Program URL:** Not Specified
- **Synopsis:**

  Jameel (Abdul Latif)
Research projects may need to adapt quickly in the context of COVID-19. The Short Term Research Management program (STReaM) makes experienced research management staff available to help researchers in the North America region navigate these challenges. STReaM will continue to accept requests for support through its regular application process. The team can offer hands-on support to help think through challenging obstacles, such as impacts to timelines, adapting to virtual research methods, and navigating difficult conversations with stakeholders. Researchers conducting projects in the North America region are invited to request this support, regardless of the project phase.

### J-PAL North America US Health Care Delivery Initiative (HCDI)

**Synopsis**

As always, HCDI is open to receiving off-cycle proposals on time-sensitive topics. HCDI welcomes proposals that focus on producing evidence that North America decision-makers can act upon promptly to respond to the current crisis. Please note that the sponsor will not accept human subjects research requiring in-person interactions with subjects.

**Contact Name**

Jameel (Abdul Latif)

**Contact Telephone**

+1 617 324 6566

**Contact Email**

vquan@povertyactionlab.org

**Sponsor Website**

Link to sponsor website

**Program URL**

Link to program URL

**Deadline Dates (ALL)**

Continuous

Not Specified

---

### Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels)

**National Science Foundation**

**NSF 20-105**

**Continuous**

Not Specified

**Contact Name**

Anthony Garza

**Contact Telephone**

aggarza@nsf.gov

**Sponsor Website**

Link to program URL

**Program URL**

Link to program URL

**Deadline Dates (ALL)**

Continuous

Not Specified
With this Dear Colleague Letter (DCL), the sponsor highlights the interest of existing programs in the Directorate for Biological Sciences (BIO) and the Directorate for Engineering (ENG) in interdisciplinary research for the development of novel biological platforms that are capable of sensing and responding to emerging infectious agents. The mechanism of sensing should be adaptable and or evolvable such that the sentinel cells, or other appropriate biotechnology solutions, are robust to a range of emergent threats, and/or can easily be reprogrammed and deployed once a new threat is identified. The platform's response should be one or more of the following: alert the user, destroy the threat, protect the host, initiate an immune response or other strategies that would ensure mitigation of the threat. Sentinel cells and organisms that detect and respond to infectious agents with expanding footprints in a host population or expanding host ranges are of particular interest, as the early detection of these infectious agents might have value in preventing future pandemics. In addition, fundamental science and technology that would lead to the development of the envisioned sentinel cells and organisms are also of interest. Investigators are encouraged not to be limited in their approach, but to think broadly about innovations leveraging biology and engineering to advance adaptable detection of emerging biological threats.

097716 COVID-19 Private Sector Engagement & Partnership Fund
Department of State SFOP000708828-May-2021 1,000,000 USD
Contact Name
Contact Telephone
Contact Email PPPCOVID19Fund@state.gov
Sponsor Website Program URL
Link to program URL Deadline Dates (ALL) 28-May-2021

The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards. Through this APS, the Department of State (DOS) announces its desire to engage private sector partners to expand and amplify the Department’s COVID-19 response. The Fund seeks to support private sector interventions and build upon private sector investments in response to the virus.

097717 RFA-TR-20-003 -- Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
National Institutes of Health/DHHS RFA-TR-20-003 Continuous 9,000,000 USD
Contact Name
Contact Telephone
The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.
| RFA-OD-20-016 -- Emergency Awards: RADx-RAD Multimodal COV

| National Institutes of Health/DHHS |
| RFA-OD-20-016 |
| 05-Oct-2020 |
| Not Specified |

| Contact Name | Elena Koustova, PhD, MBA |
| Contact Telephone | 301-496-8768 |
| Contact Email | elena.koustova@nih.gov |
| Sponsor Website | Link to program URL |

NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. The funding for this initiative is provided form the Paycheck Protection Program and Health Care Enhancement Act, 2020.

| RFA-OD-20-017 -- Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed) |
| National Institutes of Health/DHHS |
| RFA-OD-20-017 |
| 18-Aug-2020 |
| Not Specified |

[Optional] [LOI/Pre-App]
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings. This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
### Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)

**Institutes of Health/DHHS**

**RFA-OD-20-022**  
**15-Sep-2020**  
**750,000 USD**

**Contact Name** Susan Sullivan, Ph.D.  
**Contact Telephone** 301-451-3841  
**Contact Email** sullivas@nidcd.nih.gov  
**Sponsor Website**  
**Program URL** [Link to program URL](#)  
**Deadline Dates (ALL)** 15-Sep-2020

**Synopsis**

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

### RFA-OD-20-023 -- Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional)

**National Institutes of Health/DHHS**

**RFA-OD-20-023**  
**31-Aug-2020 [Optional][LOI/Pre-App]**  
**Not Specified**

**Contact Name** Bill G. Kapogiannis, MD  
**Contact Telephone** 301-402-0698  
**Contact Email** kapogiannisb@mail.nih.gov  
**Sponsor Website**  
**Program URL** [Link to program URL](#)  
**Deadline Dates (ALL)** 31-Aug-2020 [Optional][LOI/Pre-App], 30-Sep-2020

**Synopsis**

The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA seeks to support innovative research to develop...
Synopsis

novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Notice of Special Interest (NOSI):

Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool

National Institutes of Health/DHHS NOT-OD-20-152 15-Sep-2020 Not Specified

Contact Name Susan Sullivan, Ph.D.
Contact Telephone 301-451-3841
Contact Email sullivas@nidcd.nih.gov
Sponsor Website
Program URL Link to program URL
Deadline Dates (ALL) 15-Sep-2020

NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

SMARTSTM funding alerts are a service of InfoEd Global's SPINTM funding opportunities
Please do not reply directly to this message. This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message only.

Visit the Research Portal Getting Started page and enter email address under Research Listserv to update your subscription preferences at any time within the MSHS firewall.